No Data
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
Sinocare Signs Distribution Deal With Italy's Menarini Diagnostics; Shares Up 3%
A. Menarini Diagnostics and Sinocare Announce Exclusive Distribution Agreement for New Continuous Glucose Monitoring System
Investors Still Waiting For A Pull Back In Sinocare Inc. (SZSE:300298)
Sinocare Inc. (300298.SZ): The third phase of the employee stock ownership plan completed non-trading transfer.
On November 14, Guolonghui announced that on November 13, 2024, Sinocare Inc. (300298.SZ) received the "Confirmation of Securities Transfer Registration" issued by the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited. The company's repurchased shares have been transferred off-exchange to the "Sinocare Biotech Co., Ltd. - Third Phase Employee Stock Ownership Plan" special securities account on November 12, 2024, with a transfer quantity of 3,000,000 shares, accounting for 0.53% of the company's current total share capital, at a transfer price of 25.69 yuan per share. This employee stock ownership plan is saved.
Sinocare Inc.'s (SZSE:300298) Most Bullish Insider Is CEO Shao Bo Li, and Their Holdings Value Went up by 4.1% Last Week
Sinocare Inc.'s (SZSE:300298) 29% Share Price Plunge Could Signal Some Risk
